Skip to main content
PMC home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1995 Jul;163(1):49–63.

Outpatient treatment of adult asthma.

E C Kleerup 1, D P Tashkin 1
PMCID: PMC1302916  PMID: 7667983

Abstract

As a chronic disease with intermittent exacerbations, asthma is treated primarily in the outpatient setting by primary care physicians. Asthma is the result of complex and only partially understood interactions of respiratory, inflammatory, and neural cells and their mediators. The goals of asthma therapy are to prevent and relieve symptoms, allow normal activities of daily living, restore and maintain normal pulmonary function, avoid adverse effects from interventions, and minimize inconvenience and cost. These goals can be achieved through educating patients, assessing and monitoring asthma severity, avoiding or controlling asthma triggers, establishing an intervention plan for routine self-management and the management of exacerbations, and providing regular follow-up care. We present a stepped approach to asthma pharmacotherapy, emphasizing anti-inflammatory therapy--inhaled corticosteroids, cromolyn sodium, or nedocromil sodium--as a summary of recent national and international recommendations.

Full text

PDF
49

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander A. G., Barnes N. C., Kay A. B. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet. 1992 Feb 8;339(8789):324–328. doi: 10.1016/0140-6736(92)91646-p. [DOI] [PubMed] [Google Scholar]
  2. Barnes P. J., Baraniuk J. N., Belvisi M. G. Neuropeptides in the respiratory tract. Part II. Am Rev Respir Dis. 1991 Dec;144(6):1391–1399. doi: 10.1164/ajrccm/144.6.1391. [DOI] [PubMed] [Google Scholar]
  3. Barnes P. J. Effect of nedocromil sodium on airway sensory nerves. J Allergy Clin Immunol. 1993 Jul;92(1 Pt 2):182–186. doi: 10.1016/0091-6749(93)90103-m. [DOI] [PubMed] [Google Scholar]
  4. Bone M. F., Kubik M. M., Keaney N. P., Summers G. D., Connolly C. K., Burge P. S., Dent R. G., Allan G. W. Nedocromil sodium in adults with asthma dependent on inhaled corticosteroids: a double blind, placebo controlled study. Thorax. 1989 Aug;44(8):654–659. doi: 10.1136/thx.44.8.654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Boner A. L., Peroni D., Sette L., Valletta E. A., Piacentini G. Effects of allergen exposure-avoidance on inflammation in asthmatic children. Allergy. 1993;48(17 Suppl):119–124. doi: 10.1111/j.1398-9995.1993.tb04713.x. [DOI] [PubMed] [Google Scholar]
  6. Bousquet J., Michel F. B. Specific immunotherapy in asthma: is it effective? J Allergy Clin Immunol. 1994 Jul;94(1):1–11. doi: 10.1016/0091-6749(94)90064-7. [DOI] [PubMed] [Google Scholar]
  7. Bruijnzeel P. L., Warringa R. A., Kok P. T., Hamelink M. L., Kreukniet H., Koenderman L. Effects of nedocromil sodium on in vitro induced migration, activation, and mediator release from human granulocytes. J Allergy Clin Immunol. 1993 Jul;92(1 Pt 2):159–164. doi: 10.1016/0091-6749(93)90099-2. [DOI] [PubMed] [Google Scholar]
  8. Capewell S., Reynolds S., Shuttleworth D., Edwards C., Finlay A. Y. Purpura and dermal thinning associated with high dose inhaled corticosteroids. BMJ. 1990 Jun 16;300(6739):1548–1551. doi: 10.1136/bmj.300.6739.1548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Clark N. M., Evans D., Mellins R. B. Patient use of peak flow monitoring. Am Rev Respir Dis. 1992 Mar;145(3):722–725. doi: 10.1164/ajrccm/145.3.722. [DOI] [PubMed] [Google Scholar]
  10. Coffey M. J., Sanders G., Eschenbacher W. L., Tsien A., Ramesh S., Weber R. W., Toews G. B., McCune W. J. The role of methotrexate in the management of steroid-dependent asthma. Chest. 1994 Jan;105(1):117–121. doi: 10.1378/chest.105.1.117. [DOI] [PubMed] [Google Scholar]
  11. Crossman D. C., Dashwood M. R., Taylor G. W., Wellings R., Fuller R. W. Sodium cromoglycate: evidence of tachykinin antagonist activity in the human skin. J Appl Physiol (1985) 1993 Jul;75(1):167–172. doi: 10.1152/jappl.1993.75.1.167. [DOI] [PubMed] [Google Scholar]
  12. D'Alonzo G. E., Nathan R. A., Henochowicz S., Morris R. J., Ratner P., Rennard S. I. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA. 1994 May 11;271(18):1412–1416. [PubMed] [Google Scholar]
  13. Effectiveness of routine self monitoring of peak flow in patients with asthma. Grampian Asthma Study of Integrated Care (GRASSIC). BMJ. 1994 Feb 26;308(6928):564–567. [PMC free article] [PubMed] [Google Scholar]
  14. Erzurum S. C., Leff J. A., Cochran J. E., Ackerson L. M., Szefler S. J., Martin R. J., Cott G. R. Lack of benefit of methotrexate in severe, steroid-dependent asthma. A double-blind, placebo-controlled study. Ann Intern Med. 1991 Mar 1;114(5):353–360. doi: 10.7326/0003-4819-114-5-353. [DOI] [PubMed] [Google Scholar]
  15. Frew A. J. Conventional and alternative allergen immunotherapy: do they work? Are they safe? Clin Exp Allergy. 1994 May;24(5):416–422. doi: 10.1111/j.1365-2222.1994.tb00929.x. [DOI] [PubMed] [Google Scholar]
  16. Galli S. J. New concepts about the mast cell. N Engl J Med. 1993 Jan 28;328(4):257–265. doi: 10.1056/NEJM199301283280408. [DOI] [PubMed] [Google Scholar]
  17. Haahtela T., Järvinen M., Kava T., Kiviranta K., Koskinen S., Lehtonen K., Nikander K., Persson T., Selroos O., Sovijärvi A. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med. 1994 Sep 15;331(11):700–705. doi: 10.1056/NEJM199409153311103. [DOI] [PubMed] [Google Scholar]
  18. Hargreave F. E., Dolovich J., Newhouse M. T. The assessment and treatment of asthma: a conference report. J Allergy Clin Immunol. 1990 Jun;85(6):1098–1111. doi: 10.1016/0091-6749(90)90056-a. [DOI] [PubMed] [Google Scholar]
  19. Joad J. P., Ahrens R. C., Lindgren S. D., Weinberger M. M. Relative efficacy of maintenance therapy with theophylline, inhaled albuterol, and the combination for chronic asthma. J Allergy Clin Immunol. 1987 Jan;79(1):78–85. doi: 10.1016/s0091-6749(87)80020-9. [DOI] [PubMed] [Google Scholar]
  20. Kay A. B. "Helper" (CD4+) T cells and eosinophils in allergy and asthma. Am Rev Respir Dis. 1992 Feb;145(2 Pt 2):S22–S26. doi: 10.1164/ajrccm/145.2_Pt_2.S22. [DOI] [PubMed] [Google Scholar]
  21. Kikuchi Y., Okabe S., Tamura G., Hida W., Homma M., Shirato K., Takishima T. Chemosensitivity and perception of dyspnea in patients with a history of near-fatal asthma. N Engl J Med. 1994 May 12;330(19):1329–1334. doi: 10.1056/NEJM199405123301901. [DOI] [PubMed] [Google Scholar]
  22. Klaustermeyer W. B., Noritake D. T., Kwong F. K. Chrysotherapy in the treatment of corticosteroid-dependent asthma. J Allergy Clin Immunol. 1987 May;79(5):720–725. doi: 10.1016/0091-6749(87)90202-8. [DOI] [PubMed] [Google Scholar]
  23. Lal S., Dorow P. D., Venho K. K., Chatterjee S. S. Nedocromil sodium is more effective than cromolyn sodium for the treatment of chronic reversible obstructive airway disease. Chest. 1993 Aug;104(2):438–447. doi: 10.1378/chest.104.2.438. [DOI] [PubMed] [Google Scholar]
  24. Lemanske R. F., Jr Mechanisms of airway inflammation. Chest. 1992 Jun;101(6 Suppl):372S–377S. doi: 10.1378/chest.101.6_supplement.372s. [DOI] [PubMed] [Google Scholar]
  25. Martin R. J. Nocturnal asthma: circadian rhythms and therapeutic interventions. Am Rev Respir Dis. 1993 Jun;147(6 Pt 2):S25–S28. doi: 10.1164/ajrccm/147.6_Pt_2.S25. [DOI] [PubMed] [Google Scholar]
  26. Mayo P. H., Richman J., Harris H. W. Results of a program to reduce admissions for adult asthma. Ann Intern Med. 1990 Jun 1;112(11):864–871. doi: 10.7326/0003-4819-112-11-864. [DOI] [PubMed] [Google Scholar]
  27. Muranaka M., Miyamoto T., Shida T., Kabe J., Makino S., Okumura H., Takeda K., Suzuki S., Horiuchi Y. Gold salt in the treatment of bronchial asthma--a double-blind study. Ann Allergy. 1978 Feb;40(2):132–137. [PubMed] [Google Scholar]
  28. Murray A. B., Ferguson A. C. Dust-free bedrooms in the treatment of asthmatic children with house dust or house dust mite allergy: a controlled trial. Pediatrics. 1983 Mar;71(3):418–422. [PubMed] [Google Scholar]
  29. Nadel J. A. Biologic effects of mast cell enzymes. Am Rev Respir Dis. 1992 Feb;145(2 Pt 2):S37–S41. doi: 10.1164/ajrccm/145.2_Pt_2.S37. [DOI] [PubMed] [Google Scholar]
  30. Nadel J. A. Regulation of neurogenic inflammation by neutral endopeptidase. Am Rev Respir Dis. 1992 Feb;145(2 Pt 2):S48–S52. doi: 10.1164/ajrccm/145.2_Pt_2.S48. [DOI] [PubMed] [Google Scholar]
  31. Nelson H. S., Hamilos D. L., Corsello P. R., Levesque N. V., Buchmeier A. D., Bucher B. L. A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. Am Rev Respir Dis. 1993 Feb;147(2):398–404. doi: 10.1164/ajrccm/147.2.398. [DOI] [PubMed] [Google Scholar]
  32. Nierop G., Gijzel W. P., Bel E. H., Zwinderman A. H., Dijkman J. H. Auranofin in the treatment of steroid dependent asthma: a double blind study. Thorax. 1992 May;47(5):349–354. doi: 10.1136/thx.47.5.349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Nunn A. J., Gregg I. New regression equations for predicting peak expiratory flow in adults. BMJ. 1989 Apr 22;298(6680):1068–1070. doi: 10.1136/bmj.298.6680.1068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Page C. P. Mechanisms of hyperresponsiveness: platelet-activating factor. Am Rev Respir Dis. 1992 Feb;145(2 Pt 2):S31–S33. doi: 10.1164/ajrccm/145.2_Pt_2.S31. [DOI] [PubMed] [Google Scholar]
  35. Pearce F. L. Effect of nedocromil sodium on mediator release from mast cells. J Allergy Clin Immunol. 1993 Jul;92(1 Pt 2):155–158. doi: 10.1016/0091-6749(93)90098-z. [DOI] [PubMed] [Google Scholar]
  36. Platts-Mills T. A., Tovey E. R., Mitchell E. B., Moszoro H., Nock P., Wilkins S. R. Reduction of bronchial hyperreactivity during prolonged allergen avoidance. Lancet. 1982 Sep 25;2(8300):675–678. doi: 10.1016/s0140-6736(82)90709-7. [DOI] [PubMed] [Google Scholar]
  37. Ruffin R. E., Latimer K. M., Schembri D. A. Longitudinal study of near fatal asthma. Chest. 1991 Jan;99(1):77–83. doi: 10.1378/chest.99.1.77. [DOI] [PubMed] [Google Scholar]
  38. Strunk R. C. Identification of the fatality-prone subject with asthma. J Allergy Clin Immunol. 1989 Feb;83(2 Pt 1):477–485. doi: 10.1016/0091-6749(89)90137-1. [DOI] [PubMed] [Google Scholar]
  39. Toogood J. H. High-dose inhaled steroid therapy for asthma. J Allergy Clin Immunol. 1989 Feb;83(2 Pt 2):528–536. doi: 10.1016/0091-6749(89)90034-1. [DOI] [PubMed] [Google Scholar]
  40. Troyanov S., Ghezzo H., Cartier A., Malo J. L. Comparison of circadian variations using FEV1 and peak expiratory flow rates among normal and asthmatic subjects. Thorax. 1994 Aug;49(8):775–780. doi: 10.1136/thx.49.8.775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Verleden G. M., Belvisi M. G., Stretton C. D., Barnes P. J. Nedocromil sodium modulates nonadrenergic, noncholinergic bronchoconstrictor nerves in guinea pig airways in vitro. Am Rev Respir Dis. 1991 Jan;143(1):114–118. doi: 10.1164/ajrccm/143.1.114. [DOI] [PubMed] [Google Scholar]
  42. Wald J. A., Friedman B. F., Farr R. S. An improved protocol for the use of troleandomycin (TAO) in the treatment of steroid-requiring asthma. J Allergy Clin Immunol. 1986 Jul;78(1 Pt 1):36–43. doi: 10.1016/0091-6749(86)90112-0. [DOI] [PubMed] [Google Scholar]
  43. Woolcock A., Rubinfeld A. R., Seale J. P., Landau L. L., Antic R., Mitchell C., Rea H. H., Zimmerman P. Thoracic society of Australia and New Zealand. Asthma management plan, 1989. Med J Aust. 1989 Dec 4;151(11-12):650–653. [PubMed] [Google Scholar]
  44. Yeung M., O'Connor S. A., Parry D. T., Cochrane G. M. Compliance with prescribed drug therapy in asthma. Respir Med. 1994 Jan;88(1):31–35. doi: 10.1016/0954-6111(94)90171-6. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES